Edgar Filing: AERIE PHARMACEUTICALS INC - Form 4

AERIE PHARMACEUTICALS INC

Form 4 June 04, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

OMB APPROVAL

burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Mehra Anand

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to

Issuer

Symbol

AERIE PHARMACEUTICALS INC

(Check all applicable)

[AERI]

(Last) (First) 3. Date of Earliest Transaction

X_ Director X 10% Owner Other (specify Officer (give title

(Month/Day/Year) 06/02/2014

C/O SOFINNOVA VENTURES, 2800 SAND HILL

(Street)

ROAD, SUITE 150

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line)

5. Amount of

Filed(Month/Day/Year)

Form filed by One Reporting Person _X_ Form filed by More than One Reporting

6. Ownership 7. Nature of

Person

MENLO PARK, CA 94025

(City) (State) (Zip) 3. 1.Title of 2. Transaction Date 2A. Deemed 4. Securities Acquired

(Middle)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Security	(Month/Day/Year)	Execution Date, if	Transactio	on(A) or Disp	osed o	of (D)	Securities	Form: Direct	Indirect
(Instr. 3)		any	Code	(Instr. 3, 4 and 5)		Beneficially	(D) or	Beneficial	
		(Month/Day/Year)	(Instr. 8)				Owned	Indirect (I)	Ownership
							Following	(Instr. 4)	(Instr. 4)
					(A)		Reported		
					or		Transaction(s)		
			Code V	Amount	(D)	Price	(Instr. 3 and 4)		
C									See
Common	06/02/2014		J (1)	200,000	D	\$0	2,566,657	I	footnote
Stock			_	,			, ,		(2)
Common									See
Stock	06/02/2014		$J_{\underline{(3)}}$	8,022	A	\$0	8,022	I	footnote
SIUCK									(4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form

Edgar Filing: AERIE PHARMACEUTICALS INC - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)		4. Transactio	5. orNumber	6. Date Exerc Expiration D		7. Title		8. Price of Derivative	9. Nu Deriv
Security (Instr. 3)	or Exercise Price of Derivative Security	(World Day Tear)	any (Month/Day/Year)	Code (Instr. 8)	of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/		Underl Securit	lying	Security (Instr. 5)	Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
Reporting Owner Name / Matress	Director	10% Owner	Officer	Other			
Mehra Anand C/O SOFINNOVA VENTURES 2800 SAND HILL ROAD, SUITE 150 MENLO PARK, CA 94025	X	X					
HEALY JAMES C/O SOFINNOVA VENTURES 2800 SAND HILL ROAD, SUITE 150 MENLO PARK, CA 94025		X					
POWELL MICHAEL C/O SOFINNOVA VENTURES 2800 SAND HILL ROAD, SUITE 150 MENLO PARK, CA 94025		X					
Buatois Eric C/O SOFINNOVA VENTURES 2800 SAND HILL ROAD, SUITE 150 MENLO PARK, CA 94025		X					
SOFINNOVA VENTURE PARTNERS VII L P C/O SOFINNOVA VENTURES 2800 SAND HILL ROAD, SUITE 150 MENLO PARK, CA 94025		X					
Sofinnova Management VII, L.L.C. C/O SOFINNOVA VENTURES		X					

Reporting Owners 2

Edgar Filing: AERIE PHARMACEUTICALS INC - Form 4

2800 SAND HILL ROAD, SUITE 150 MENLO PARK, CA 94025

Signatures

/s/ Nathalie Auber, Attorney-in-Fact for Anand Mehra					
**Signature of Reporting Person	Date				
/s/ Nathalie Auber, Attorney-in-Fact for James Healy					
**Signature of Reporting Person	Date				
/s/ Nathalie Auber, Attorney-in-Fact for Eric Buatois					
**Signature of Reporting Person	Date				
/s/ Nathalie Auber, Attorney-in-Fact for Michael Powell					
**Signature of Reporting Person	Date				
/s/ Nathalie Auber, Attorney-in-Fact for Sofinnova Venture Partners VII, L.P.					
**Signature of Reporting Person	Date				
/s/ Nathalie Auber, Attorney-in-Fact for Sofinnova Management VII, L.L.C.	06/04/2014				
**Signature of Reporting Person	Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares disposed of by way of distribution to the partners of Sofinnova Venture Partners VII, L.P. ("SV VII") pro rata and without consideration, in accordance with its partnership agreement (the "Distribution").
- The securities are owned directly by SV VII. Sofinnova Management VII, L.L.C. ("SV VII LLC"), the general partner of SV VII, James
 Healy, Michael Powell, and Eric Buatois, the managing members of SV VII LLC, and Anand Mehra, a director of the Issuer, may be
 deemed to have shared voting and dispositive power over the shares owned by SV VII. Such persons and entities disclaim beneficial
 ownership over the shares owned by SV VII except to the extent of any pecuniary interest therein.
- (3) Shares acquired in connection with the Distribution of such shares to the partners of SV VII.
- Shares are owned directly by SV VII LLC, and James Healy, Michael Powell, and Eric Buatois, the managing members of SV VII LLC, and Anand Mehra, a director of the Issuer, may be deemed to have shared voting and dispositive power over the shares owned by SV VII LLC. Such persons and entities disclaim beneficial ownership over the shares owned by SV VII LLC except to the extent of any pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3